‹ All episodes

The BioInsights Podcast

Modernizing cell therapy manufacturing to reduce vein-to-vein times

July 26, 2023 David Backer, CEO Curate Biosciences Season 2 Episode 8

Chapters

How have you seen CAR-T cell therapies evolve over time?

What are the key challenges and priorities for CAR-T cell manufacture?

Why are the initial steps in apheresis or debulking important?

How does DCS microfluidics differ from other techniques?

How can DCS optimize the expansion of T cells?

Does cell separation impact subsequent genome editing steps?

Can manufacturing processes help ensure clinical efficacy?

Info

The BioInsights Podcast

Modernizing cell therapy manufacturing to reduce vein-to-vein times

Jul 26, 2023 Season 2 Episode 8

David Backer, CEO Curate Biosciences

Charlotte Barker (Editor, BioInsights) speaks with Curate Biosciences’ CEO David Backer and CTO Tony Ward about the need for CAR-T cell therapy manufacturing to evolve, and how a new cell separation technique could boost efficiency.

Share Episode

Share on Facebook Share on Twitter Share on LinkedIn Download

Subscribe

Apple Podcasts Spotify More

Listen on

Apple Podcasts Spotify Amazon Music Overcast Castro Castbox +

Share Episode

Share on Facebook Share on Twitter Share on LinkedIn

Charlotte Barker (Editor, BioInsights) speaks with Curate Biosciences’ CEO David Backer and CTO Tony Ward about the need for CAR-T cell therapy manufacturing to evolve, and how a new cell separation technique could boost efficiency.